Treatment options for NSCLC greatly developed in the last decades with the advance in targeted therapies against mutated genes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS-1) and v-raf murine sarcoma viral oncogene homolog B (BRAF) (2–7). This evidence concerns the gene BRAF and non-small cell lung carcinoma.